Skip to content

Move for Your Mind - Pilot Trial

Home Exercise, Vitamin D and Dalcroze Eurhythmics for Seniors With Mild Cognitive Impairment (MCI) or Mild Dementia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02279316
Acronym
MFYM - P
Enrollment
19
Registered
2014-10-31
Start date
2014-10-31
Completion date
2016-09-30
Last updated
2016-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fall Prevention, Mild Cognitive Impairment, Mild Dementia

Keywords

Dalcroze eurhythmics, home exercise, vitamin D, mild cognitive impairment, MCI, mild dementia

Brief summary

Move for your mind is a single blind, 3-arm randomized controlled clinical pilot trial. The study aims to test the effect of a weekly Dalcroze eurhythmics program (arm 1) and a home strength exercise program (arm 2) against control (no exercise) on the rate of falling, quality of life, gait performance and cognitive function. All groups receive vitamin D. In addition the study shall test the feasibility of the recruitment and the interventions in this target population. The study includes 60 seniors, age 65 and older, with mild cognitive impairment or mild dementia. Participants are recruited by the memory clinic of City Hospital Waid. During the 12 months follow-up, participants will have 3 clinical visits (baseline, 6 and 12 month). Despite major efforts the target population is very difficult to recruit and adherence to treatment is low. We therefore decided to stop recruitment and to use this trial as a pilot trial for future clinical trials of the same topic.

Detailed description

Primary objective To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) will decrease rate of falls in seniors with MCI or mild dementia compared with the control group. Secondary objectives Objective 1: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) decreases 12-month risk of falling at least once in seniors with MCI or mild dementia compared with the control group. Objective 2: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) improves cognitive func-tion and alertness in seniors with MCI or mild dementia compared with the control group. Objective 3: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) decreases gait variability in seniors with MCI or mild dementia compared with the control group. Objective 4: To test whether the Jaques-Dalcroze eurhythmics program (1 hour a week for 12 months) and/or the simple home exercise program (3 × 30 min a week for 12 months) improves quality of life in seniors with MCI or mild dementia compared with the control group.

Interventions

DRUGVi-De 3

All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.

OTHERJaques-Dalcroze eurhythmics

The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.

OTHERHome exercise program

The home exercise program is a strengthening program that will consist of five simple exercises.

Sponsors

Waid City Hospital, Zurich
CollaboratorOTHER
University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 65+ years * Diagnosed with MCI or mild dementia by the memory clinic of City Hospital Waid

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Rate of falls (any falls, low trauma falls, injurious falls) during 12 month follow-upat month 2, 4, 6, 8, 10 and 12 after baselineA fall is defined as unintentional coming to rest on the ground, floor, or other lower level (coming to rest against furniture or a wall is not considered a fall). All reported incident falls will be ascertained every 2 month (phone calls at 2, 4, 8 and 10 months and clinical visits at 6 and 12 months after baseline) with a questionnaire evaluating the circumstances of each fall and injuries associated with it. Participants will also receive a diary to record any new health event including a fall. The diary will serve as a supplementary tool to falls evaluation minimizing potential recall bias.

Secondary

MeasureTime frameDescription
Number of participants who fell at least once during 12 months of follow upat month 2, 4, 6, 8, 10 and 12 after baseline
Gait variability (stride time, stride length and gait speed)Baseline, 6 & 12 monthsassessed by a GAITRite analysis system
Cognitive functionBaseline, 6 & 12 monthsassessed using the Montreal Cognitive Assessment (MoCA)
AlertnessBaseline, 6 & 12 monthsAlertness will be assessed using the two subtests alertness and split alertness of the test of attentional performance (TAP)
Quality of lifeBaseline, 6 and 12 monthsevaluated using the SF-36 questionnaire

Other

MeasureTime frameDescription
progression of MCI/mild dementia6 &12 monthsany progression of the cognitive disorder to a more severe state ( will be confirmed based on medical records of the memory clinic of Waid City Hospital. Evaluation of this endpoint will be supported by information from the MoCA and the TAP subtests at baseline, 6, and 12 months clinical visits.
Musculoskeletal painbaseline, 6 and 12 monthassessed using McGill pain map. Number of painful joints will be assessed using a joint map.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026